Leukaemic peripheral blood plasma and bone marrow plasma: comparison of influence on lymphocyte proliferation.
Peripheral blood plasma from some children with untreated acute lymphoblastic leukaemia (ALL) exerted an inhibitory effect in vitro on phytohaemagglutinin-induced lymphocyte transformation of normal peripheral blood lymphocytes. This occurred at concentrations beyond that required for optimal response as judged by reduction of blast cell formation and tritiated thymidine and tritiated uridine incorporation into DNA and RNA, respectively. In contrast, bone marrow plasma from these patients was non-inhibitory or contained significantly less inhibitory activity. Bone marrow plasma from the majority of healthy controls was superior to their peripheral blood plasma in enhancing phytohaemagglutinin-induced mitogenesis. The difference between an individual's bone marrow- and peripheral blood-derived plasma in enhancing proliferation of patient and healthy control cells was significantly greater amongst the patients than the healthy control group; this was attributed mainly to the increased inhibitory activity of ALL peripheral blood plasma compared with normal plasma. Medium conditioned by phytohaemagglutinin-stimulated normal peripheral blood lymphocytes was effective in neutralizing the inhibitory activity of ALL peripheral blood plasma. Taken together, these in vitro results are at least suggestive that in vivo, in healthy subjects, the rapidly proliferating cells in the bone marrow and the 'resting' blood cells in the circulation may be under the influence of a fine balance of different types and/or levels of humoral growth stimulatory and inhibitory factors and that in ALL an unstable balance of these factors exists. The decreased proliferation of circulating blast cells compared with bone marrow blasts in ALL may be attributed, at least in part, to exposure to the different levels of inhibitor(s) in the circulation and bone marrow as demonstrated in vitro by our results.
Schultz
J C
JC
Division of Pediatric Hematology/Oncology, University of Wisconsin, Madison 53792-4108, USA.
D001853:Bone Marrow / Q000503:physiopathology*; D002460:Cell Line / Q000187:drug effects; D002675:Child, Preschool; D003470:Culture Media / Q000494:pharmacology; D006801:Humans; D008213:Lymphocyte Activation / Q000502:physiology*; D008214:Lymphocytes / Q000166:cytology / Q000378:metabolism; D010835:Phytohemagglutinins / Q000494:pharmacology; D010949:Plasma / Q000502:physiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood*; D012313:RNA / Q000378:metabolism; D012016:Reference Values; D013997:Time Factors; D014529:Uridine / Q000378:metabolism
D003470:Culture Media; D010835:Phytohemagglutinins; D012313:RNA; D014529:Uridine